ATE148456T1 - Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese - Google Patents

Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese

Info

Publication number
ATE148456T1
ATE148456T1 AT94916021T AT94916021T ATE148456T1 AT E148456 T1 ATE148456 T1 AT E148456T1 AT 94916021 T AT94916021 T AT 94916021T AT 94916021 T AT94916021 T AT 94916021T AT E148456 T1 ATE148456 T1 AT E148456T1
Authority
AT
Austria
Prior art keywords
glycolipid synthesis
deoxygalactonojirimycin
derivatives
inhibit
deoxygalactonojirimycin derivatives
Prior art date
Application number
AT94916021T
Other languages
German (de)
English (en)
Inventor
Frances M Glycobiology I Platt
Parks Road South
Gabrielle R Neises
Raymond A Glycobiology In Dwek
Terry D Glycobiology I Butters
Original Assignee
Searle & Co
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/061,645 external-priority patent/US5399567A/en
Application filed by Searle & Co, Monsanto Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE148456T1 publication Critical patent/ATE148456T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT94916021T 1993-05-13 1994-05-11 Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese ATE148456T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/061,645 US5399567A (en) 1993-05-13 1993-05-13 Method of treating cholera
US08/102,654 US6291657B1 (en) 1993-05-13 1993-08-05 Deoxygalactonojirimycin derivatives

Publications (1)

Publication Number Publication Date
ATE148456T1 true ATE148456T1 (de) 1997-02-15

Family

ID=26741316

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916021T ATE148456T1 (de) 1993-05-13 1994-05-11 Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese

Country Status (11)

Country Link
US (3) US6291657B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0698012B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3636363B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE148456T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU6783294A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2159988C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69401658T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0698012T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2097653T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3022554T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994026714A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU1734600A (en) * 1998-11-17 2000-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of glycosphingolipids that promote hiv-1 entry into cells
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
CA2378776A1 (en) 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
AU1840101A (en) * 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
JP4575156B2 (ja) 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
EP1554245B1 (en) 2002-07-17 2012-09-26 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
GB0229476D0 (en) * 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
EP2857036B1 (en) * 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
BRPI0416216A (pt) * 2003-11-12 2006-12-26 Amicus Therapeutics Inc composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
US20050256168A1 (en) * 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
WO2005123055A2 (en) * 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
EP1896083B1 (en) 2005-05-17 2016-03-02 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
KR20090040906A (ko) * 2006-08-02 2009-04-27 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 리포솜 치료
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
KR20120059447A (ko) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
WO2012083435A1 (en) 2010-12-23 2012-06-28 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
WO2012129651A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2726492B1 (en) 2011-06-27 2017-11-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032187A1 (en) * 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
AU2013337570B2 (en) 2012-10-31 2018-01-18 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9827189B2 (en) 2013-01-09 2017-11-28 Amicus Therapeautics, Inc. Stable parenteral DNJ compositions
EA201992807A1 (ru) 2017-06-01 2020-05-20 Идорсия Фармасьютиклз Лтд Кристаллическая форма n-бутилдеоксигалактоноджиримицина
WO2021061701A1 (en) 2019-09-25 2021-04-01 Teva Pharmaceuticals International Gmbh Solid state forms of lucerastat salts and process for preparation thereof
WO2022132992A1 (en) 2020-12-16 2022-06-23 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
WO2025017212A1 (en) 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Udp-glucose ceramide glucosyltransferase synthase (ugcg) inhibitors in the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
ATE126696T1 (de) 1985-12-23 1995-09-15 Hutchinson Fred Cancer Res Regulierung der retroviralen replikation, infektion und pathogenese.
US4849430A (en) 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
WO1992000277A1 (fr) 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
US5128347A (en) * 1990-10-18 1992-07-07 Monsanto Company Glycosidase inhibiting 1,4-dideoxy-4-fluoronojirimycin

Also Published As

Publication number Publication date
EP0698012B1 (en) 1997-01-29
ES2097653T3 (es) 1997-04-01
DE69401658T2 (de) 1997-06-12
WO1994026714A1 (en) 1994-11-24
GR3022554T3 (en) 1997-05-31
AU6783294A (en) 1994-12-12
US5580884A (en) 1996-12-03
EP0698012A1 (en) 1996-02-28
CA2159988A1 (en) 1994-11-24
US6291657B1 (en) 2001-09-18
DK0698012T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-02-17
US5786368A (en) 1998-07-28
JP3636363B2 (ja) 2005-04-06
CA2159988C (en) 2007-01-09
DE69401658D1 (de) 1997-03-13
JPH08510244A (ja) 1996-10-29

Similar Documents

Publication Publication Date Title
ATE148456T1 (de) Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese
ATE196140T1 (de) Substituierte benzylaminoquinuclidine als substanz p antagonisten
DK0915866T3 (da) Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
DE3688559D1 (de) Zwischenprodukte in der synthese von diaminandrostan-derivaten.
ES447509A1 (es) Perfeccionamientos en amortiguadores-distanciadores para ca-bles suspendidos.
GR3001441T3 (en) Pyrrolidinylamide ester derivative having anti-prolyl endopeptidase activity, its synthesis and use and a pharmaceutical composition containing it
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
MX9400194A (es) Materiales fototermograficos.
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
ES8706371A1 (es) Procedimiento para preparar derivados de tetrazol con actividad insecticida
TR199800243T1 (xx) Prolil endopeptidaz inhibit�rleri.
ATE196464T1 (de) Benzol-derivate, verwendbar für ischämische erkrankungen
FI951588A0 (fi) Öljykoostumuksia
GB9513331D0 (en) Matrix metalloproteinase inhibitors
CA1273946C (en) ANTICONVULSANT GAMMA-THIOBUTYROLACTONE DERIVATIVES
GB2341862A (en) Histamine H3 receptor ligands
ES8203358A1 (es) Metodo de producir lactamas antihipertensoras
ATE159934T1 (de) Azoxycyanobenzol-derivate und ihre verwendung als fungizide
GB1512620A (en) Derivatives of dithiepino(1,4)(2,3-c)pyrrole
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.
NO990285L (no) Tienylcykloheksan-derivater for tienylcykloheksyl-syntese
ES2192342T3 (es) 2-(2,6-dioxo-3-fluoropiperidin-3-il)-isoindolinas sustituidas y su uso para reducir los niveles de tnfalfa.
ES2092714T3 (es) Derivados de indol.
DK0850217T3 (da) Fremgangsmåde til fremstilling af arylalkynyl-N-hydroxy-carbamid-derivater med lipoxygenaseinhibitor-aktivitet
TW333554B (en) Benzidine derivative and electrophotosensitive material using the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee